The World's Greatest Investing Community
Results 21 - 30 of 516 : Previous 1 2 3 4 5 6 7 8 9 Next
Checking the Quality of Hospira's Growth
These two simple metrics can save you a lot of pain.
Are Shorts Watching This Number at Celgene?
Look here for a clue.
Why the Street Should Love Gilead Sciences' Earnings
All cash flow is not created equal.
The 8 Highest Potential Returns in Biotechnology
What the numbers tell us.
Here's 1 Reason Gilead Sciences Looks Weak
Keep your eye on margins.
Agios and Celgene: Anatomy of an Ultra-Valuable Biotech Marriage
An unprecedented cancer drug development deal.
5-Star ETFs Poised to Pop: iShares Nasdaq Biotechnology
Market-trouncing returns could be written in this 5-Star.
Micromet Maxes Out These 2 Metrics
These two simple metrics can save you a lot of pain.
Buybacks That Are Better Than Dividends
Buybacks are a good choice for drugmakers despite their shortcomings.
We Don't Care if It's the First Lupus Drug in 50 Years
The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK